Due to the link between obesity, insulin resistance and cancer, several FDA-approved antidiabetic therapies such as insulin sensitizers (thiazolidinediones), insulin secretagogues (sulfonylureas) and biguanides, which have been associated with the decrease in cancer incidence, are being investigated as anti-cancer therapies [5,6,7]. Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.